La vía canónica PI3K/AKT/mTOR y sus alteraciones en cáncer

Autores/as

  • Franklin Aldecoa Clínica Internacional San Borja. Lima, Perú. Universidad Peruana de Ciencias Aplicadas (UPC), Facultad de Medicina. Lima, Perú. Médico Oncólogo, Maestría en Medicina. https://orcid.org/0000-0003-3401-3689
  • Ávila J Universidad Peruana de Ciencias Aplicadas (UPC), Facultad de Medicina. Lima, Perú. Médico cirujano, Coordinador de Línea de Estructura y Función. https://orcid.org/0000-0001-7161-9554

DOI:

https://doi.org/10.24265/horizmed.2021.v21n4.15

Palabras clave:

Cáncer, Fosfatidilinositol 3-quinasa, Proteínas proto-oncogénicas c-akt, Serina-treonina quinasas TOR

Resumen

La vía PI3K/AKT/mTOR participa en múltiples procesos celulares fundamentales para la célula. Algunas mutaciones genéticas de los componentes de esta vía se han asociado a diversas enfermedades humanas: las más importantes son los carcinomas de mama, tiroides y endometrio, el glioblastoma multiforme, el cáncer de próstata y los linfomas. La vía canónica PI3K/AKT/mTOR se ha estudiado ampliamente en los últimos años. Sin embargo, el conocimiento de la complejidad de sus componentes principales y su interrelación con los elementos de otras vías va en aumento. Por ello, es importantes actualizar cada cierto tiempo la información disponible para la comprensión de este mecanismo. Así mismo, se están y se han desarrollado numerosos ensayos con medicinas selectivas en búsqueda de un tratamiento más inteligente para las enfermedades asociadas a alteraciones de esta vía. Por tanto, realizamos una revisión de esta vía de transducción con el objetivo de tener una visión cercana de su funcionamiento, sus alteraciones y enumerar algunas moléculas promisorias para ser utilizadas en futuros tratamientos.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Heldin C-H, Lu B, Evans R, Gutkind JS. Signals and receptors. Cold Spring Harb Perspect Biol. 2016; 8(4): a005900.

Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017; 170(4): 605-35.

Ortega MA, Fraile-Martínez O, Asúnsolo Á, Buján J, García-Honduvilla N, Coca S. Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. J Oncol. 2020; 2020: 9258396.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646-74.

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013; 339(6127): 1546-58.

Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 2010; 347: 21-41.

Toomey S, Carr A, Mezynski MJ, Elamin Y, Rafee S, Cremona M, et al. Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. J Transl Med. 2020; 18(1): 99.

Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505(7484): 495-501.

Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. Semin Cancer Biol. 2019; 59: 125-32.

Paolo GD, Camilli PD. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006; 443(7112): 651-7.

Prestwich GD. Phosphoinositide signaling; from affinity probes to pharmaceutical targets. Chem Biol. 2004; 11(5): 619-37.

Nascimbeni AC, Codogno P, Morel E. Phosphatidylinositol-3-phosphate in the regulation of autophagy membrane dynamics. FEBS J. 2017; 284(9): 1267-78.

Rubio RG, Ransom RF, Malik S, Yule DI, Anantharam A, Smrcka AV. Phosphatidylinositol 4-phosphate is a major source of GPCR-stimulated phosphoinositide production. Sci Signal. 2018; 11(547): eaan1210.

Poli A, Zaurito AE, Abdul-Hamid S, Fiume R, Faenza I, Divecha N. Phosphatidylinositol 5 Phosphate (PI5P): From Behind the Scenes to the Front (Nuclear) Stage. Int J Mol Sci. 2019; 20(9): 2080.

Sun Y, Thapa N, Hedman AC, Anderson RA. Phosphatidylinositol 4,5-bisphosphate: targeted production and signaling. Bioessays. 2013; 35(6): 513-22.

Jin N, Lang MJ, Weisman LS. Phosphatidylinositol 3,5-bisphosphate: regulation of cellular events in space and time. Biochem Soc Trans. 2016; 44(1): 177-84.

Li H, Wu X, Hou S, Malek M, Kielkowska A, Noh E, et al. Phosphatidylinositol-3,4-Bisphosphate and Its Binding Protein Lamellipodin Regulate Chemotaxis of Malignant B Lymphocytes. J Immunol. 2016; 196(2): 586-95.

Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8): 606-19.

Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010; 11(5): 329-41.

Auger KR, Serunian LA, Soltoff SP, Libby P, Cantley LC. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell. 1989; 57(1): 167-75.

Ruderman NB, Kapeller R, White MF, Cantley LC. Activation of phosphatidylinositol 3-kinase by insulin. Proc Natl Acad Sci U S A. 1990; 87(4): 1411-5.

Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7): 489-501.

Fayard E, Tintignac LA, Baudry A, Hemmings BA. Protein kinase B/Akt at a glance. J Cell Sci. 2005; 118(Pt 24): 5675-8.

Liu S-L, Wang Z-G, Hu Y, Xin Y, Singaram I, Gorai S, et al. Quantitative Lipid Imaging Reveals a New Signaling Function of Phosphatidylinositol-3,4-Bisphophate: Isoform- and Site-Specific Activation of Akt. Mol Cell. 2018; 71(6): 1092-104.e5.

Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science. 1998; 279(5351): 710-4.

Hart JR, Vogt PK. Phosphorylation of AKT: a mutational analysis. Oncotarget. 2011; 2(6): 467-76.

Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell. 2008; 30(2): 203-13.

Kawakami Y, Nishimoto H, Kitaura J, Maeda-Yamamoto M, Kato RM, Littman DR, et al. Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem. 2004; 279(46): 47720-5.

Lynch DK, Ellis CA, Edwards PA, Hiles ID. Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene. 1999; 18(56): 8024-32.

Toker A, Newton AC. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem. 2000; 275(12): 8271-4.

Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129(7): 1261-74.

Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017; 169(3): 381-405.

Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007; 32(4-5): 577-95.

Haar ET, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct Biol. 2001; 8(7): 593-6.

Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell. 2001; 7(6): 1321-7.

Cole A, Frame S, Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J. 2004; 377(Pt 1): 249-55.

Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol. 2001; 21(3): 952-65.

Calnan DR, Brunet A. The FoxO code. Oncogene. 2008; 27(16): 2276-88.

Heide LPVD, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J. 2004; 380(Pt 2): 297-309.

Benayoun BA, Caburet S, Veitia RA. Forkhead transcription factors: key players in health and disease. Trends Genet. 2011; 27(6): 224-32.

Zech R, Kiontke S, Mueller U, Oeckinghaus A, Kümmel D. Structure of the Tuberous Sclerosis Complex 2 (TSC2) N Terminus Provides Insight into Complex Assembly and Tuberous Sclerosis Pathogenesis. J Biol Chem. 2016; 291(38): 20008-20.

Hartleben G, Müller C, Krämer A, Schimmel H, Zidek LM, Dornblut C, et al. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma. EMBO J. 2018; 37(21): e98589.

Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009; 122(Pt 20): 3589-94.

Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017; 168(6): 960-76.

Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010; 1804(3): 433-9.

Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149(2): 274-93.

Franke TF. PI3K/Akt: getting it right matters. Oncogene. 2008; 27(50): 6473-88.

Phillips J, Domingo E. PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide). Atlas Genet Cytogenet Oncol Haematol. 2019; 23(4): 76-9.

Thorpe LM, Spangle JM, Ohlson CE, Cheng H, Roberts TM, Cantley LC, et al. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α. Proc Natl Acad Sci U S A. 2017; 114(27): 7095-100.

Rodgers SJ, Ferguson DT, Mitchell CA, Ooms LM. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases. Biosci Rep. 2017; 37(1): BSR20160432.

Myers MP, Pass I, Batty IH, Kaay JVD, Stolarov JP, Hemmings BA, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A. 1998; 95(23): 13513-8.

Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998; 7(3): 507-15.

Longy M. PTEN (phosphatase, tensin homolog deleted on chromosome ten): Atlas Genet Cytogenet Oncol Haematol. 1999; 3(3): 128-9.

Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM. INPP4B: the new kid on the PI3K block. Oncotarget. 2011; 2(4): 321-8.

Woolley JF, Dzneladze I, Salmena L. Phosphoinositide signaling in cancer: INPP4B Akt(s) out. Trends Mol Med. 2015; 21(9): 530-2.

Yi KH, Lauring J. Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity. Oncotarget. 2016; 7(4): 4241-51.

Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007; 448(7152): 439-44.

Mancini ML, Lien EC, Toker A. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. Oncotarget. 2016; 7(14): 17301-13.

Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer. 2008; 98(9): 1533-5.

Mancinelli R, Carpino G, Petrungaro S, Mammola CL, Tomaipitinca L, Filippini A, et al. Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases. Oxid Med Cell Longev. 2017; 2017: 4629495.

Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ, Emanuel BS, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993; 5(3): 230-5.

Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994; 54(11): 2869-72.

Slany RK. The molecular biology of mixed lineage leukemia. Haematologica. 2009; 94(7): 984-93.

Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018; 32(2): 273-84.

Mikse OR, Blake DC, Jones NR, Sun Y-W, Amin S, Gallagher CJ, et al. FOXO3 encodes a carcinogen-activated transcription factor frequently deleted in early-stage lung adenocarcinoma. Cancer Res. 2010; 70(15): 6205-15.

Herzog CR, Blake DC, Mikse OR, Grigoryeva LS, Gundermann EL. FoxO3a gene is a target of deletion in mouse lung adenocarcinoma. Oncol Rep. 2009; 22(4): 837-43.

Mieulet V, Lamb RF. Tuberous sclerosis complex: linking cancer to metabolism. Trends Mol Med. 2010; 16(7): 329-35.

Pymar LS, Platt FM, Askham JM, Morrison EE, Knowles MA. Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Hum Mol Genet. 2008; 17(13): 2006-17.

Huynh H, Hao H-X, Chan SL, Chen D, Ong R, Soo KC, et al. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. Mol Cancer Ther. 2015; 14(5): 1224-35.

Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat Cell Biol. 2010; 12(9): 814-22.

Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, et al. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 2007; 67(24): 11712-20.

Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019; 12(1): 71.

Zhang M, Jang H, Nussinov R. PI3K inhibitors: review and new strategies. Chem Sci. 2020; 11(23): 5855-65.

Kienle DL, Stilgenbauer S. Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Expert Opin Pharmacother. 2020; 21(8): 917-29.

Markham A. Alpelisib: First Global Approval. Drugs. 2019; 79(11): 1249-53.

Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020; 47(6): 4587-629.

Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 2015; 11(7): 1946-54.

##submission.downloads##

Publicado

2021-12-11

Cómo citar

Aldecoa, F., & Ávila J. (2021). La vía canónica PI3K/AKT/mTOR y sus alteraciones en cáncer. Horizonte Médico (Lima), 21(4), e1547. https://doi.org/10.24265/horizmed.2021.v21n4.15

Número

Sección

Artículos de revisión